AbbVie ups bid for drugmaker Shire to £30 billion AbbVie raised its offer for Shire to £30.1 billion today, hoping to win over its reluctant target after three earlier offers were rejected. Business • 08 Jul 14
AbbVie ups bid for drugmaker Shire to £30 billion AbbVie raised its offer for Shire to £30.1 billion today, hoping to win over its reluctant target after three earlier offers were rejected. Business • 08 Jul 14
Patent win helps Shire as AbbVie plots next move Shire has a new reason to argue it is worth more after a US court backed patent claims on its top-selling drug Vyvanse. Business • 25 Jun 14
Patent win helps Shire as AbbVie plots next move Shire has a new reason to argue it is worth more after a US court backed patent claims on its top-selling drug Vyvanse. Business • 25 Jun 14
Shire flags new drugs in defence to AbbVie Shire has flagged the promise of existing and new drugs as evidence that AbbVie's $46 billion offer undervalued the company. Business • 23 Jun 14
Shire flags new drugs in defence to AbbVie Shire has flagged the promise of existing and new drugs as evidence that AbbVie's $46 billion offer undervalued the company. Business • 23 Jun 14
Shire rejects latest bid approach from AbbVie US drugmaker AbbVie has confirmed it had made a bid approach to Shire, which was rejected by the British group's board. Business • 20 Jun 14
Shire rejects latest bid approach from AbbVie US drugmaker AbbVie has confirmed it had made a bid approach to Shire, which was rejected by the British group's board. Business • 20 Jun 14
Shire shares rise on takeover bid expectations Shares in Shire rose today on bid expectations after Reuters reported that the drugmaker had hired investment bank Citi as a defence adviser. Business • 17 Jun 14
Shire shares rise on takeover bid expectations Shares in Shire rose today on bid expectations after Reuters reported that the drugmaker had hired investment bank Citi as a defence adviser. Business • 17 Jun 14
Shire to pay $4.2 billion for ViroPharma London-listed Shire is to buy ViroPharma for $4.2 billion, attracted by a pipeline of potentially lucrative drugs to treat rare diseases. Business • 11 Nov 13
Shire to pay $4.2 billion for ViroPharma London-listed Shire is to buy ViroPharma for $4.2 billion, attracted by a pipeline of potentially lucrative drugs to treat rare diseases. Business • 11 Nov 13
